Hexarelin

BHuman Studies

Growth hormone releasing peptide · 6 amino acids

Not FDA ApprovedPrescription RequiredWADA Banned

Hexarelin is one of the most potent synthetic GH secretagogues. Research also suggests it has direct cardioprotective effects independent of its GH-releasing properties.

Mechanism of Action

Activates GHS receptors for GH release. Uniquely, also binds CD36 scavenger receptors in cardiac tissue, providing direct cardioprotective effects independent of GH signaling.

Benefits

Most potent GH release among GHRPs
Direct cardioprotective effects via CD36 binding
Improved cardiac function in heart failure models
Anti-atherosclerotic properties observed

Not Medical Advice — Research-Reported Information Only

This content is for informational purposes only and does not constitute medical advice.

Hexarelin — Dosing in Published Research

Reported Routes: Subcutaneous injection, Intravenous

Clinical studies used 1-2 mcg/kg IV or SC. Desensitization of GH response observed after weeks of continuous use.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

Elevated cortisol and prolactin
GH response desensitization with chronic use
Flushing
Water retention

Considering Peptide Research?

Hexarelin is not FDA-approved. Always consult a licensed healthcare provider before considering any peptide.

Learn About Finding a Provider

Always Consult a Professional

Research & Evidence

RCTAnnals of Medicine, 1999

Cardiovascular effects of hexarelin

Hexarelin improved left ventricular ejection fraction in patients with severe GH deficiency through direct cardiac effects

PMID: 10195554

AnimalEndocrinology, 2004

Hexarelin CD36 binding and cardioprotection

Hexarelin binds cardiac CD36 receptors, protecting against ischemia-reperfusion injury independent of GH release

PMID: 15331606

Compare Hexarelin With

Hexarelin vs Ipamorelin

Hexarelin vs GHRP-2

Hexarelin vs GHRP-6

Hexarelin vs Sermorelin

References

1. Cardiovascular effects of hexarelin. Annals of Medicine, 1999. “Hexarelin improved left ventricular ejection fraction in patients with severe GH deficiency through direct cardiac effects” [PMID: 10195554]
2. Hexarelin CD36 binding and cardioprotection. Endocrinology, 2004. “Hexarelin binds cardiac CD36 receptors, protecting against ischemia-reperfusion injury independent of GH release” [PMID: 15331606]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.